These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 1352252)
21. Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Akiyama K; Kanzaki A; Tsuchida K; Ujike H Schizophr Res; 1994 Jun; 12(3):251-7. PubMed ID: 8054317 [TBL] [Abstract][Full Text] [Related]
22. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain. Ericson H; Ross SB Eur J Pharmacol; 1992 Jun; 226(2):157-61. PubMed ID: 1353452 [TBL] [Abstract][Full Text] [Related]
23. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine. Kanzaki A; Okumura K; Ujike H; Tsuchida K; Akiyama K; Otsuki S J Neural Transm Gen Sect; 1992; 90(2):137-44. PubMed ID: 1361127 [TBL] [Abstract][Full Text] [Related]
24. N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. Wikström H; Andersson B; Elebring T; Svensson K; Carlsson A; Largent B J Med Chem; 1987 Dec; 30(12):2169-74. PubMed ID: 2824773 [TBL] [Abstract][Full Text] [Related]
25. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
27. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats. Shuto T; Seeman P; Kuroiwa M; Nishi A Eur J Neurosci; 2008 May; 27(10):2551-7. PubMed ID: 18489579 [TBL] [Abstract][Full Text] [Related]
28. DTG and (+)-3-PPP inhibit a ligand-activated hyperpolarization in mammalian neurons. Bobker DH; Shen KZ; Surprenant A; Williams JT J Pharmacol Exp Ther; 1989 Dec; 251(3):840-5. PubMed ID: 2574744 [TBL] [Abstract][Full Text] [Related]
29. Multiple vascular effects of sigma and PCP ligands: inhibition of amine uptake and contractile responses. Massamiri T; Duckles SP J Pharmacol Exp Ther; 1990 Apr; 253(1):124-9. PubMed ID: 2158542 [TBL] [Abstract][Full Text] [Related]
30. GBR-12909 and fluspirilene potently inhibited binding of [3H] (+)3-PPP to sigma receptors in rat brain. Contreras PC; Bremer ME; Rao TS Life Sci; 1990; 47(22):PL133-7. PubMed ID: 1980329 [TBL] [Abstract][Full Text] [Related]
31. Up-regulation of rat cortical sigma receptors after subchronic administration of rimcazole and 1,3-di(2-tolyl)guanidine. Manallack DT; Beart PM Neuropharmacology; 1988 Nov; 27(11):1201-3. PubMed ID: 2849732 [TBL] [Abstract][Full Text] [Related]
32. Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats. Takahashi S; Miwa T; Horikomi K Neurosci Lett; 2000 Jul; 289(1):21-4. PubMed ID: 10899399 [TBL] [Abstract][Full Text] [Related]
33. sigma Receptor antagonists block the development of sensitization to cocaine. Ujike H; Kuroda S; Otsuki S Eur J Pharmacol; 1996 Jan; 296(2):123-8. PubMed ID: 8838447 [TBL] [Abstract][Full Text] [Related]
34. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol. Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390 [TBL] [Abstract][Full Text] [Related]
35. Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. Mizoguchi H; Yamada K; Mouri A; Niwa M; Mizuno T; Noda Y; Nitta A; Itohara S; Banno Y; Nabeshima T J Neurochem; 2007 Sep; 102(5):1548-1560. PubMed ID: 17472698 [TBL] [Abstract][Full Text] [Related]
36. Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice. Mori T; Ito S; Kita T; Narita M; Suzuki T; Sawaguchi T Eur J Pharmacol; 2006 Feb; 532(1-2):81-7. PubMed ID: 16464448 [TBL] [Abstract][Full Text] [Related]
37. Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations. Hjorth S; Clark D; Carlsson A Life Sci; 1985 Aug; 37(7):673-84. PubMed ID: 2410756 [TBL] [Abstract][Full Text] [Related]
38. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. Tam SW; Steinfels GF; Gilligan PJ; Schmidt WK; Cook L J Pharmacol Exp Ther; 1992 Dec; 263(3):1167-74. PubMed ID: 1361572 [TBL] [Abstract][Full Text] [Related]
39. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D1 receptor agonist. Shuto T; Kuroiwa M; Hamamura M; Yabuuchi K; Shimazoe T; Watanabe S; Nishi A; Yamamoto T Neuropharmacology; 2006 Jun; 50(8):991-7. PubMed ID: 16563442 [TBL] [Abstract][Full Text] [Related]
40. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Ujike H; Onoue T; Akiyama K; Hamamura T; Otsuki S Psychopharmacology (Berl); 1989; 98(1):89-92. PubMed ID: 2498964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]